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Abstract 
Asthma and chronic obstructive pulmonary 
disease are common diseases both characterised by 
airflow obstruction. Over recent decades the 
prevailing belief was that asthma and COPD were 
distinct diseases that can be easily distinguished and 
require different treatments. This stimulated basic 
scientific research aimed at obtaining a better 
understanding of both diseases, particularly COPD 
that had been neglected. The downside of this 
approach was that it resulted in the exclusion of 
patients from clinical trials that exhibited features of 
both diseases. However, it has been increasingly 
recognised that these patients are common in 
everyday clinical practice and that their exclusion 
from clinical trials meant that therapeutic decisions 
were not evidence based. The concept of the asthma 
COPD overlap syndrome is an attempt to develop 
diagnostic criteria for patients with features of both 
asthma and COPD. This is a necessary starting 
point from which to design studies to investigate the 
clinical features, aetiology, pathophysiology and 
prognosis of these patients, and ultimately 
determine treatment strategies. However, from the 
outset the concept of asthma COPD overlap 
syndrome has been controversial and has not gained 
universal acceptance.  
In this review we will describe current 
definitions and concepts of the asthma COPD 
overlap syndrome and explore how our 
understanding of this syndrome may develop in the 
future. 
Introduction 
Asthma and chronic obstructive pulmonary 
disease (COPD) are chronic pulmonary diseases 
with similar clinical features and both are 
characterised by varying degrees of airflow 
obstruction. However, their aetiologies, pathology, 
progression and treatment responses differ 
markedly and guidelines produced by expert bodies 
have stressed the differences between the 2 diseases 
and the importance of diagnostic clarity. The Global 
Initiative for Asthma (GINA) defines asthma as ‘a 
heterogenous disease, usually characterised by 
chronic airway inflammation. It is defined by the 
history of respiratory symptoms such as wheeze, 
shortness of breath, chest tightness and cough that 
vary over time and in intensity, together with 
variable expiratory airflow limitation.’1 The Global 
Initiative for Obstructive Lung Disease (GOLD) 
defines COPD as ‘COPD is a common, preventable 
and treatable disease that is characterised by 
persistent respiratory symptoms and airflow 
limitation that is due to airway and/or alveolar 
abnormalities usually caused by significant 
exposure to noxious particles or gases.2’ These 
definitions are deliberately broad so as to be 
applicable in a wide range of countries and 
healthcare settings, including resource-poor 
environments where access to more sophisticated 
diagnostic tools may be limited. However, the 
disadvantage of such broad definitions is that 
patients may have clinical features that are included 
in the definitions of both asthma and COPD. For 
example some patients with a diagnosis of asthma 
may have ‘persistent airflow obstruction’ rather 
than ‘variable expiratory airflow limitation’ and 
patients with COPD can have symptoms that vary 
and variable airflow obstruction.3 Clinicians face 
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considerable diagnostic and therapeutic confusion 
when managing patients who have features of both 
asthma and COPD. Patients also face confusion 
when given different diagnostic labels of asthma or 
COPD by different clinicians. Therefore, experts 
have attempted to reach consensus regarding the 
diagnostic labels and clinical features that can be 
used to describe patients with features of both 
asthma and COPD. However, this approach remains 
controversial and the topic of fierce debate. 
Asthma COPD overlap syndrome (ACOS) 
Various terms have been used to describe 
patients with features of both asthma and COPD 
including asthma with chronic bronchitis, combined 
asthma and COPD, mixed asthma and COPD, 
asthma with irreversible airflow obstruction, COPD 
with asthmatic features and COPD with a reversible 
component. It was recognised that there are patients 
with features that ‘overlap’ both asthma and COPD 
as far back as 1995 in the COPD guidelines of the 
American Thoracic Society.4 However over the next 
two decades both clinical and basic science research 
focused on defining the unique clinical, 
pathological and inflammatory features of asthma 
and COPD, resulting in the prevailing view that 
they are two clearly distinct diseases. This was 
reflected in the design of clinical trials in which 
patients with overlapping features of both diseases 
were excluded and only patients with ‘pure’ asthma 
or COPD were included. However it became 
increasingly clear that such an approach resulted in 
only a minority of patients with asthma and COPD 
fulfilling the inclusion criteria for clinical trials.5-6 
A large number of patients were excluded because 
they had clinical features of, or risk factors for, both 
asthma and COPD. A review published in 2009 by 
Gibson et al exploring this issue coined the term the 
‘overlap syndrome of asthma and COPD.’7 This 
triggered a host of studies and expert reviews over 
the following years and in 2015 GINA and GOLD 
published a joint document proposing the term 
asthma COPD overlap syndrome (ACOS).8 
However there has not been universal acceptance of 
the term or even the need for another diagnostic 
label in addition to asthma and COPD.9-10 Therefore 
debate continues how best to describe the range of 
patients with obstructive airway disease, 
particularly those that do not fit classical 
descriptions of asthma and COPD. 
Definitions of ACOS 
The GINA/GOLD document has described 
ACOS as ‘characterised by persistent airflow 
limitation with several features usually associated 
with asthma and several features usually associated 
with COPD’ (8). The document emphasized that 
this is not a definition of a new disease but a 
‘description for clinical use’, and that a specific 
definition cannot be developed until more is known 
about underlying mechanisms. It listed features that 
are individually characteristic of asthma and COPD 
and recommended that if a patient has features of 
both, this is suggestive of ACOS. So for example 
early age of onset, variable airflow obstruction, 
normal lung function between symptoms and 
symptoms that vary seasonally would favour 
asthma, whereas later age of onset, persistent 
airflow limitation and exposure to a risk factor such 
as tobacco smoke would favour COPD. While this 
is an easy to use pragmatic approach to the problem 
it has several drawbacks. Firstly the document did 
not define how many shared clinical features of 
asthma and COPD are required to diagnose ACOS, 
therefore this remains a subjective assessment on 
the part of the clinician. Secondly it is clear that 
patients with very different phenotypic (and 
probably mechanistic) features can be included 
under an umbrella of ACOS. For example a patient 
with lifelong asthma who has never smoked and has 
persistent symptoms and airflow obstruction would 
have features of both asthma and COPD. Equally a 
patient with a personal and family history of asthma 
and a smoking history with some variability in 
symptoms and airflow obstruction would tick 
different boxes but also fulfil criteria for ACOS. 
Other expert societies have produced their 
own definitions of ACOS. In 2016 a global expert 
panel of specialists and generalists from North 
America, Western Europe and Asia proposed a set 
of diagnostic criteria consisting of 3 major criteria 
(1: Persistent airflow limitation (post-
bronchodilator FEV1/FVC <0.70 or < lower limit of 
normal) in individuals 40 years of age or older; 2: 
≥10 pack years of smoking or equivalent and 3: A 
documented history of asthma before 40 years of 
age or bronchodilator response ≥400 mL) and three 
minor criteria (1: Documented history of atopy or 
allergic rhinitis; 2: A bronchodilator response of 
≥200 mL and 12% or greater on 2 different 
occasions and 3: A peripheral eosinophil count of 
300/µL or greater).11 Patients who meet all 3 major 
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criteria and at least 1 minor criterion should be 
considered as having ACOS. Other national 
societies have also produced diagnostic criteria.12 
Therefore it is clear that although there is broad 
agreement on what constitute the key clinical 
features of ACOS, as yet there is still no universally 
agreed definition. In the absence of such a 
definition epidemiological, mechanistic and 
therapeutic studies will continue to be difficult and 
plagued by the use of different definitions. 
Epidemiology 
As there is no agreed definition of AOCS, its 
prevalence in studies will depend on which 
definition is used. Most epidemiological studies 
have simply determined the proportion of patients 
with a physician diagnosis of both asthma and 
COPD and used this as a measure of the prevalence 
of ACOS. A review of general population studies 
from a number of different countries estimated the 
population prevalence of ACOS to range from 1.6% 
to 4.5%.13 In the USA the prevalence of patients 
with a physician diagnosis of both asthma and 
COPD has been reported as 2.7%.14 The prevalence 
of ACOS defined in this way appears to increase 
with age. In a survey of a random sample of the 
Italian population the prevalence of patients with a 
dual diagnosis was 1.6% in the 20-44-year age 
group, 2.1% in the 45-64-year age group and 4.5% 
in the 65-84-year age group.15 Among people aged 
> 40 years in five Latin American cities the
prevalence of patients with a dual diagnosis was
1.7%.16 
Other studies have investigated the prevalence 
of dual diagnoses in patients with an existing 
diagnosis of asthma or COPD. A systematic review 
of five studies reported that the mean prevalence of 
ACOS defined in this way among patients with 
asthma or COPD was 20%.10 In a survey from the 
USA of 3,486 patients, 1,585 (45.4%) had asthma 
alone, 1,294 (37.1%) had COPD alone, and 607 
(17.4%) had ACOS.17 In a literature review the 
prevalence of ACOS among patients with COPD 
ranged from 12.1% to 55.2%, and the prevalence of 
ACOS among asthma patients ranged from 13.3% 
to 61.0%.13 A meta-analysis of 27 studies identified 
COPD patients with a physician diagnosis of 
asthma or evidence of reversible airflow obstruction 
(≥ 12% and at least 200ml change in FEV1 from 
baseline, or ≥ 20% change in PEF or airway hyper-
responsiveness).18 Using these criteria 27% of 
COPD patients were diagnosed with ACOS. 
Compared with patients with COPD only, ACOS 
subjects were younger, had a shorter smoking 
history and a higher BMI, but there were no 
differences between the groups in spirometry and 
the 6-minute walking distance. Among 1,488,613 
adults in the USA with a diagnostic code of either 
COPD or asthma, 21.3% had a diagnosis of both 
asthma and COPD.19 Considering that these studies 
were carried out in diverse populations and used 
different definitions of asthma, COPD and ACOS, 
it is not surprising that the results are so varied. 
More definitive epidemiological data on the 
prevalence of ACOS will be impossible to obtain 
before a stringent, universally-agreed definition is 
available.  
Burden of disease 
Although the prevalence of ACOS continues 
to be debated, epidemiological studies have 
consistently demonstrated that patients with a dual 
diagnosis of asthma and COPD have worse 
outcomes compared with those with a single 
diagnosis. Studies from a number of different 
countries have reported that ACOS is associated 
with greater symptoms,15,20-21 worse lung 
function,22 more frequent exacerbations,20-22 more 
hospitalisations,15,17,19,23 greater prevalence of 
anxiety and depression,17,19 impaired activity15,17 
and more comorbidities.19-20 Some of these findings 
may relate to the increased diagnosis of ACOS with 
increasing age. However, it is clear that the burden 
of disease associated with a dual diagnosis of 
asthma and COPD is high and needs to be 
addressed.  
Therapeutic Implications 
Ascribing a diagnosis of asthma, COPD or 
ACOS to individual patients is not just of semantic 
or academic interest, but has a direct impact on 
treatment decisions. Clinical trials in asthma and 
COPD have utilised strict inclusion and exclusion 
criteria to ensure that a relatively ‘pure’ population 
is recruited. Patients with clinical features of both 
asthma and COPD have been excluded from clinical 
trials, resulting in a patient population that is not 
representative of the wider population seen in 
routine clinical practice. Halpin et al reported that 
the median eligibility of 36 893 patients with COPD 
for participation in 31 randomised controlled trials 
was only 23 %.24 Other studies have reported 
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eligibility rates ranging from 17% to 42%.25 The 
commonest reason for exclusion was a history of 
asthma, allergic conditions or atopy. In asthma even 
lower rates of suitability have been recorded with a 
lack of reversibility and a smoking history being 
common reasons for exclusion.5-6 These data 
suggest that the majority of ‘real life’ patients have 
features of, or risk factors for, both asthma and 
COPD, but are excluded from clinical trials. The 
systematic exclusion of these patients from clinical 
trials means that the effects of treatments in this 
population are unknown. In view of the high burden 
of symptoms, exacerbations and hospitalisations 
among these patients clinical trials are urgently 
needed that include these patients to determine the 
optimum treatment strategies. 
Until relatively recently there appeared to be 
increasing convergence in treatments for asthma 
and COPD, with clinical trials reporting that inhaled 
corticosteroid (ICS)/long-acting β2-agonists 
(LABA) are beneficial in COPD,26 and long-acting 
muscarinic antagonists (LAMA) improve symptoms 
and lung function in asthma.27 Therefore such a 
convergence would suggest a diminished 
importance for distinguishing asthma, COPD and 
ACOS. However, a number of recent clinical 
findings have changed treatment recommendations 
in asthma and COPD, particularly regarding the role 
of ICS in COPD. There is evidence that ICS are 
inappropriately overprescribed in COPD, and 
current treatment guidelines are not being adhered 
to.28 This has become of growing concern as 
evidence has emerged of an increased risk of 
pneumonia associated with ICS use in COPD.29 At 
the same time as evidence has emerged of potential 
adverse effects of ICS in COPD, studies have 
reported that ICS withdrawal is safe in COPD,30 and 
that LABA/LAMA are equivalent to ICS/LABA in 
regards to exacerbation reduction.31 Together these 
emerging data have led to efforts to reduce 
inappropriate use of ICS in COPD.32 However, this 
could lead to underuse or withdrawal of ICS in 
patients with ACOS, with potential detrimental 
effects. For now this remains a hypothetical concern 
but it highlights the importance of including 
patients with features of both asthma and COPD in 
clinical trials and the danger in extrapolating the 
results of trials that recruit a highly select group of 
patients to the wider population seen in clinical 
practice. 
Future directions 
Although the concept of ACOS has helped to 
focus research attention on a previously neglected 
group of patients, concerns remain about adding 
another diagnostic label to an increasingly 
confusing landscape of airway diseases, phenotypes 
and endotypes.9 An alternative approach that has 
been proposed is to treat patients based on a 
personalised medicine approach and abandon 
disease labels.33-34 Under such an approach patients’ 
history and risk factors would be assessed through a 
comprehensive history and examination and the 
presence of airflow obstruction confirmed with 
spirometry. The focus would then be on identifying 
‘treatable traits’ and comorbidities, rather than 
basing treatment on a diagnostic label.35 These traits 
may be pulmonary (e.g. eosinophilic airway 
inflammation, airflow obstruction, bacterial 
infection, chronic bronchitis), extra-pulmonary (e.g. 
obesity, gastro-oesophageal reflux disease, upper 
airway disease) or behavioural/lifestyle factors (e.g. 
smoking, allergen exposure, air pollution).35 There 
is evidence that current diagnostic labels are 
inadequate in describing and distinguishing 
inflammatory patterns in patients with chronic 
airway disease36 and therefore the alternative 
approach has the advantages of recognising the 
clinical and biological complexity of chronic airway 
disease. It is hoped that this will then have the 
potential to offer an evidence-based and cost-
effective approach to treatment. 
However, a personalised medicine approach to 
airway disease also has potential disadvantages in 
that it is likely to require increased and more 
sophisticated diagnostic testing leading to increased 
costs. Such an approach may not be achievable in 
resource-poor settings or in primary care even in 
high-income countries where many such patients 
are currently managed. Such an approach also 
requires a better understanding of the biology of 
airway diseases to select the best biomarkers that 
can correctly phenotype diseases and predict 
treatment response. The recent failure of a 
biomarker-directed treatment to reduce 
exacerbations in asthma highlights the need for 
further research into understanding the biology of 
chronic airway diseases.37 
Conclusions 
Many patients with chronic airflow limitation 
seen in routine clinical practice do not fit easily into 
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neat definitions of asthma and COPD. As these 
patients were excluded from clinical trials the 
optimum treatment for these patients is not known. 
Characterisation of these patients as having asthma-
COPD overlap syndrome has focussed attention on 
a previously neglected group of patients, but 
widespread acceptance of the term ACOS has been 
hampered by the inability to agree on a standardised 
definition. Debate continues as to whether a 
personalised medicine approach is superior to the 
use of diagnostic labels such as asthma, COPD and 
ACOS. It may be that currently ACOS is a useful 
concept but as our understanding of the biology and 
mechanisms of chronic airway diseases increases 
and robust biomarkers are discovered, then it may 
become either much better defined, or possibly, 
redundant.  
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